ArticleAfrican health sciences2019
Exploration of hypoglycemic effect of an extract from leaves of a plant from Tunisian pharmacopeia:
Article in African health sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 11 citations in OpenAlex.
- Antihyperglycemic Activity ofMolecules (Basel, Switzerland) · 2025Article
- The effect ofJournal of medicine and life · 2025Article
- NCD epidemic and sexual reproductive health issues in the infectious disease world.African health sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesA lot of research has been directed towards medicinal plants which are considered as a source of multiple phytotherapic substances endowed with hypoglycemic activities that could be used to treat diabetes and its complications. Our study was carried out in Wistar rats to investigate the hypoglycemic effect of n-Butanol Fraction from
methodsTwo experimental models were used in rats: orally induced hyperglycemia (OGTT) and isolated perfused liver (IPRL).
resultsBFACME at 550 mg/kg BW dose significantly reduced fasting glucose level in normal rats as compared to controls. The decrease of glycaemia was 12.6% more significant than that obtained with the standard drug glibenclamide (10 mg/kg BW), an oral antidiabetic preparation belonging to sulfonylurea class. In OGTT model, BFACME at the highest doses of 550 and 400 mg/kg BW significantly reduced the postprandial hyperglycemic peak compared to controls. In the IPRL model, treatment with BFACME significantly decreased glucose concentrations after 30 min of perfusion with 30 mM glucose solely when insulin was present. The higher doses of BFACME lead to glucose concentration at basal level as early as 90 min, while the lowest dose does not restore this concentration even to t = 120min. The best initial glucose concentration retrieval was obtained with 0.7 mg BFACME/mL/g liver. At this dose, BFACME improves the decrease of glucose level caused by only insulin by about 18%.
conclusionThe BFACME appears to exert a hypoglycemic activity by potentiating the insulin action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.